Hebei Medical University Fourth Hospital
154
46
51
16
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 60/100
3.2%
5 terminated/withdrawn out of 154 trials
76.2%
-10.3% vs industry average
14%
21 trials in Phase 3/4
6%
1 of 16 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (154)
Laparoscopic Staging for Stage III Gastric Cancer
Role: collaborator
Sedation in ICU Patients With Mechanical Ventilation
Role: collaborator
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
Role: lead
Dalpiciclib With or Without Entinostat and Letrozole in HR+/HER2- Early Breast Cancer
Role: lead
Modified Tumor-free Techniques Operation to Cervical Cancer
Role: collaborator
Trilaciclib in Combination With Chemotherapy in Patients With CDK4/6-Dependent Solid Tumors
Role: lead
Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics
Role: lead
Laparoscopic Gastrectomy With D2 Lymphadenectomy Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) or Not
Role: collaborator
Short-course Radiotherapy in TNT Combined With Enlonstobart for pMMR LARC
Role: lead
Real-world Study on the Prevention of Neutropenia After Tumor Treatment With Mecapegfilgrastim Injection
Role: lead
ctDNA Monitoring Guides the Treatment of NSCLC With Befotertinib Combined With Radiotherapy
Role: lead
CAPOX and Bevacizumab With or Without Primary Tumor Radiotherapy and Iparomlimab and Tuvonralimab as First-line Treatment for RAS-Mutant/MSS Metastatic Rectal Cancer
Role: collaborator
Postmastecomy Internal Mammary Nodal Irradiation for High-risk Breast Cancer Patients
Role: collaborator
A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer
Role: collaborator
Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer
Role: lead
A Phase II Study of Anlotinib and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Lung Cancer.
Role: collaborator
Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction
Role: collaborator
Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC)
Role: lead
The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma
Role: lead
Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer
Role: lead